Structure-Guided Design of Potent and Mutant-Selective EGFR L858R/T790M Inhibitors

Through structure-guided design approach based on our previous work on mutant-selective EGFR inhibitor (compound 9), we have designed and generated a novel 1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one scaffold, followed by introduction of alkyl groups contacting the Met790 gatekeeper residue into the C4-position to keep the selectivity for the EGFRL858R/T790M over EGFRWTleading to discovery of one of the most potent compound 20a20a not only showed remarkable selectivity of enzyme inhibition for EGFRL858R/T790M over EGFRWT, but also strongly inhibited the proliferation of H1975 cellswhile significantly less effective on A431 cell lines. A further preliminary in vivo antitumor efficacy evaluation on 20a suggested that it significantly inhibited tumor growth in H1975 NSCLC xenograft mouse model via po dosing at 50 mg/kg/day for 14 days. Considering the encouraging enzymatic and cellular selectivity and in vivo antitumor efficiency of compound 20athis agent might be a promising lead compound for further optimization as selective EGFRL858R/T790M inhibitor to overcome T790M resistance mutation. The results also provide more insights for designing new classes of mutant-selective EGFR inhibitors. Further pre-clinical evaluationfor the candidate compound are in progress and will be performed in due course.

User Login


Database


PTID

Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号